Tasquinimod + cabazitaxel in heavily pre-treated men with mCRPC

Posted on January 23, 2012 by Sitemaster

According to media information from Active Biotech this morning, the company has initiated an early stage, combination therapy trial (the so-called CATCH trial) of their investigational agent tasquinimod + cabazitaxel (Jevtana®) for the treatment of men with heavily pre-treated, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , | Leave a Comment »

Cabazitaxel gets final approval for marketing in Europe

Posted on March 21, 2011 by Sitemaster

According to a media release from Sanofi-Aventis, the European Commission has authorized marketing of cabazitaxel (Jevtana®) in all 27 countries of the European Union in combination with prednisone or prednisolone. … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , | 4 Comments »

European Medicines Agency approves cabazitaxel

Posted on January 21, 2011 by Sitemaster

According to a media release from Sanofi-Aventis and a report on the Reuters web site today, the European Medicines Agency (EMEA) has approved cabazitaxel (Jevtana) … READ MORE …

Filed under: Drugs in development, Management, Treatment | Tagged: , , , , | Leave a Comment »

Report provides final results of the TROPIC trial of cabazitaxel

Posted on October 2, 2010 by Sitemaster

Cabazitaxel (Jevtana®) has recently been approved in the USA for the treatment of men with castration-resistant prostate cancer who have progressive disease following treatment with standard first-line chemotherapy (docetaxel + prednisone). … READ MORE …

Filed under: Drugs in development, Management, Treatment, Uncategorized | Tagged: , , | 1 Comment »

US FDA approves cabazitaxel for late-stage prostate cancer

Posted on June 17, 2010 by Sitemaster

Somewhat “out of the blue,” the US Food and Drug Administration (FDA), earlier today, approved Sanofi-Aventis’s “second-generation” taxane, cabazitaxel (Jevtana®) in combination with prednisone for the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) who have already progressed after treatment with docetaxel. … READ MORE …

Filed under: Drugs in development, Management, Treatment | Tagged: , , , , , | 2 Comments »

Follow

Get every new post delivered to your Inbox.

Join 824 other followers